**Table 6.**

*Frequency of main clinical complaints (%) in patients before the start, one and three months after IFN-γ therapy in patients of the 1st group (1st subgroup—with the level of induced IFN-γ closer to the upper limit of the reference values).*

subfebrile temperature, sore throat, chills, sweating, and decreased concentration. The rest of the complaints tended to decrease or remain unchanged. The dynamics of clinical complaints in the patients of the 2nd subgroup is presented in **Table 7**.


#### **Table 7.**

*Frequency of clinical complaints (%) in patients before the start, one and three months after IFN-γ therapy in patients of the 1st group (2nd subgroup—with the level of induced IFN-γ closer to the lower limit of the reference values).*

*Recombinant Human Interferon-Gamma: Prospects for the Treatment of Chronic Epstein-Barr… DOI: http://dx.doi.org/10.5772/intechopen.101325*

In the 2nd subgroup of patients, one and three months after IFN-γ therapy, a significant positive dynamics of the main clinical complaints were observed, in particular, a decrease in lymphadenitis, sore throat, chills, sweating, mucus drainage along the back of the throat, stomatitis, joint pain, decreased concentration attention, sleep disorders. That is, patients with an initially reduced level of induced IFN-γ before starting IFN-γ therapy have a more pronounced response to the therapy.

When analyzing the clinical picture, we revealed that in the group of patients with a higher level of induced IFN-γ production at the time of initiation of therapy complaints were more intensive and occurred with higher frequency (**Figures 4** and **5**).

**Figure 4.**

*Frequency of main clinical complaints (%) in patients before the start, one and three months after IFN-γ therapy in patients with CEBVI in the 1st subgroup.*

**Figure 5.**

*Frequency of clinical complaints (%) in patients before the start, one and three months after IFN-γ therapy in patients with CVEBI in the 2nd subgroup.*
